Jesper Fjølner

Jesper Fjølner

Auto-generated profile, based on publicly available information

Jesper Fjølner

Aarhus Univ Hosp, Dept Intens Care, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2017 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
HFHans Flaatten
Hans Flaatten
DLDylan W. De Lange
Dylan W. De Lange
AMAlessandro Morandi
Alessandro Morandi
FAFinn H. Andersen
Finn H. Andersen
Antonio ArtigasAntonio Artigas
Antonio Artigas
OGon behalf of the VIP1 study group
on behalf of the VIP1 study group

29 November 2019 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
BGBertrand Guidet
Bertrand Guidet
DLDylan W. de Lange
Dylan W. de Lange
ABAriane Boumendil
Ariane Boumendil
SLSusannah Leaver
Susannah Leaver
XWXimena Watson
Ximena Watson
HFHans Flaatten
Hans Flaatten

6 December 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MKMette Krag
Mette Krag
SMSøren Marker
Søren Marker
APAnders Perner
Anders Perner
JWJørn Wetterslev
Jørn Wetterslev
MWMatt P. Wise
Matt P. Wise
MMMorten H. Møller
Morten H. Møller
Prophylaxis for gastrointestinal stress ulceration is frequently given to patients in the intensive care unit (ICU), but its risks and benefits are unclear. In this European, multicenter, parallel-group, blinded trial, we randomly assigned adults who had been admitted to the ICU for an acute condition (i.e., an unplanned admission) and who were at risk for gastrointestinal bleeding to receive 40 mg of intravenous pantoprazole (a proton-pump inhibitor) or placebo daily during the ICU stay. The primary outcome was death by 90 days after randomization. A total of 3298 patients were enrolled; 1645 were randomly assigned to the pantoprazole group and 1653 to the placebo group. Data on the primary outcome were available for 3282 patients (99.5%). At 90 days, 510 patients (31.1%) in the pantoprazole group and 499 (30.4%) in the placebo group had died (relative risk, 1.02; 95% confidence interval [CI], 0.91 to 1.13; P=0.76). During the ICU stay, at least one clinically important event (a composite of clinically important gastrointestinal bleeding, pneumonia, Clostridium difficile infection, or myocardial ischemia) had occurred in 21.9% of patients assigned to pantoprazole and 22.6% of those assigned to placebo (relative risk, 0.96; 95% CI, 0.83 to 1.11). In the pantoprazole group, 2.5% of patients had clinically important gastrointestinal bleeding, as compared with 4.2% in the placebo group. The number of patients with infections or serious adverse reactions and the percentage of days alive without life support within 90 days were similar in the two groups. Among adult patients in the ICU who were at risk for gastrointestinal bleeding, mortality at 90 days and the number of clinically important events were similar in those assigned to pantoprazole and those assigned to placebo. (Funded by Innovation Fund Denmark and others; SUP-ICU ClinicalTrials.gov number, NCT02467621.)

17 May 2018 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
BGBertrand Guidet
Bertrand Guidet
HFHans Flaatten
Hans Flaatten
ABAriane Boumendil
Ariane Boumendil
Alessandro MorandiAlessandro Morandi
Alessandro Morandi
FAFinn H. Andersen
Finn H. Andersen
DLDylan W. De Lange
Dylan W. De Lange

19 April 2021 in Critical Care
Verified
Journal Article
Open access
PDF file
CJChristian Jung
Christian Jung
HFHans Flaatten
Hans Flaatten
JFJesper Fjølner
Jesper Fjølner
RBRaphael Romano Bruno
Raphael Romano Bruno
Bernhard WernlyBernhard Wernly
Bernhard Wernly
BGBertrand Guidet
Bertrand Guidet
Background: The COVID-19 pandemic has led highly developed healthcare systems to the brink of collapse due to the large numbers of patients being admitted into hospitals. One of the potential prognostic indicators in patients with COVID-19 is frailty. The degree of frailty could be used to assist both the triage into intensive care, and decisions regarding treatment limitations. Our study sought to determine the interaction of frailty and age in elderly COVID-19 ICU patients. Methods: A prospective multicentre study of COVID-19 patients ≥ 70 years admitted to intensive care in 138 ICUs from 28 countries was conducted. The primary endpoint was 30-day mortality. Frailty was assessed using the clinical frailty scale. Additionally, comorbidities, management strategies and treatment limitations were recorded. Results: The study included 1346 patients (28% female) with a median age of 75 years (IQR 72–78, range 70–96), 16.3% were older than 80 years, and 21% of the patients were frail. The overall survival at 30 days was 59% (95% CI 56–62), with 66% (63–69) in fit, 53% (47–61) in vulnerable and 41% (35–47) in frail patients (p < 0.001). In frail patients, there was no difference in 30-day survival between different age categories. Frailty was linked to an increased use of treatment limitations and less use of mechanical ventilation. In a model controlling for age, disease severity, sex, treatment limitations and comorbidities, frailty was independently associated with lower survival. Conclusion: Frailty provides relevant prognostic information in elderly COVID-19 patients in addition to age and comorbidities. Trial registration Clinicaltrials.gov: NCT04321265, registered 19 March 2020.

1 August 2019 in Journal of Critical Care
Verified
Journal Article
Closed access
CJChristian Jung
Christian Jung
Bernhard WernlyBernhard Wernly
Bernhard Wernly
JMJohanna Müssig
Johanna Müssig
MKMalte Kelm
Malte Kelm
ABAriane Boumendil
Ariane Boumendil
HFHans Flaatten
Hans Flaatten